KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.Lancet HIVPMID 39008999无 PMCID2024-Aug0.98未发现恶性肿瘤人群证据。待处理
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.EBioMedicinePMID 39018755PMC112870122024-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials.Expert Rev Respir MedPMID 39106052无 PMCID2024-Aug0.98未发现恶性肿瘤人群证据。待处理
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.ESMO OpenPMID 39121814PMC113626422024-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for multiple sclerosis.Mult SclerPMID 39143826无 PMCID2024-Aug0.98未发现恶性肿瘤人群证据。待处理
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.Health Technol AssessPMID 39250424PMC114033772024-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL).PLoS MedPMID 39137167PMC113215882024-Aug0.98未发现恶性肿瘤人群证据。待处理
A phase III, multicentre, randomised, investigator-masked, cross-over, comparative, non-inferiority trial evaluating the efficacy and tolerability of generic preservative-free Latanoprost (Polpharma S.A.) compared to Xalatan® (Pfizer) in patients with ocular hypertension or primary open-angle glaucoma.BMC OphthalmolPMID 39075412PMC112852912024-Jul-290.98未发现恶性肿瘤人群证据。待处理
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.Arthritis Res TherPMID 39075620PMC112851352024-Jul-290.85The study is a randomized Phase 3 trial of a drug intervention with original results, but it is for rheumatoid arthritis, not human malignant neoplasm (oncology). It also lacks the required time-to-event efficacy endpoint.待处理
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.LancetPMID 38971175无 PMCID2024-Jul-270.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial.LancetPMID 38991582无 PMCID2024-Jul-270.98未发现恶性肿瘤人群证据。待处理
Efficacy, safety and immunogenicity of the biosimilar etanercept compared to the reference formulation original etanercept in patients with rheumatoid arthritis: An open-label, randomized, comparative, multicenter study.Medicine (Baltimore)PMID 39058806PMC112723222024-Jul-260.98未发现恶性肿瘤人群证据。待处理
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.BMC CancerPMID 39060961PMC112825932024-Jul-260.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.BMC CancerPMID 39054462PMC112707572024-Jul-250.97仅有 Phase I/II 证据,未达到确证性随机试验标准。待处理
Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.VaccinePMID 38762360PMC112526652024-Jul-250.98未发现恶性肿瘤人群证据。待处理
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.N Engl J MedPMID 39047240PMC113340542024-Jul-250.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.J Infect DisPMID 39052718PMC112720422024-Jul-250.98未发现恶性肿瘤人群证据。待处理
Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.J Infect DisPMID 39052726PMC112720882024-Jul-250.98未发现恶性肿瘤人群证据。待处理
Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections.J Infect DisPMID 39052734PMC112720622024-Jul-250.98未发现恶性肿瘤人群证据。待处理
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.J Infect DisPMID 39052748PMC112720832024-Jul-250.98未发现恶性肿瘤人群证据。待处理
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).BMC CancerPMID 39054430PMC112707602024-Jul-250.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.BMC CancerPMID 39054467PMC112707622024-Jul-250.95While this is a phase III randomized trial with drug interventions reporting original results, it does not meet the required time-to-event endpoint criterion. The primary endpoint was ORR (objective response rate), a binary measure, and the secondary endpoints were safety/tolerability and an exploratory pharmacodynamic endpoint. No survival or progression-free survival endpoints (which are time-to-event outcomes) were reported or analyzed in this publication. The deterministic review signal 'no_time_to_event_signal' is confirmed.待处理
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.BMC CancerPMID 39054485PMC112707592024-Jul-250.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.BMC CancerPMID 39054491PMC112707642024-Jul-250.95The study is an eligible randomized Phase III trial in oncology with a drug intervention, but the primary endpoint is ORR, not a time-to-event outcome. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint.待处理
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.RMD OpenPMID 39059811PMC112849392024-Jul-250.98未发现恶性肿瘤人群证据。待处理
Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial.Nat CommunPMID 39048547PMC112695762024-Jul-240.98未发现恶性肿瘤人群证据。待处理
Development and application of a qualitative rapid analysis framework in a hybrid trial within primary care.BMJ OpenPMID 39053958PMC112849352024-Jul-240.98未发现恶性肿瘤人群证据。待处理
Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116).J Clin OncolPMID 38709986PMC115138872024-Jul-200.95This is a Phase III randomized, placebo-controlled trial in breast cancer survivors with a drug intervention, but it lacks a primary or key secondary time-to-event efficacy endpoint. The primary outcome is cognitive function (HVLT-R score) analyzed with mixed-effects repeated measures ANCOVA, not a survival or time-to-event outcome. Therefore, it does not meet the criterion for a time-to-event endpoint required for KM digitization.待处理
CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.J Clin OncolPMID 38828957PMC112685572024-Jul-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies.Clin Exp DermatolPMID 37820029无 PMCID2024-Jul-190.98未发现恶性肿瘤人群证据。待处理
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.N Engl J MedPMID 38884324无 PMCID2024-Jul-180.98未发现恶性肿瘤人群证据。待处理
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.N Engl J MedPMID 39018531无 PMCID2024-Jul-180.95The study is a Phase 3 randomized trial of drug interventions for Crohn's disease, not a human malignant neoplasm. It does not meet the core oncology eligibility criterion.待处理
Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.N Engl J MedPMID 39018532PMC116948282024-Jul-180.98未发现恶性肿瘤人群证据。待处理
Entomological effects of attractive targeted sugar bait station deployment in Western Zambia: vector surveillance findings from a two-arm cluster randomized phase III trial.Malar JPMID 39026236PMC112646792024-Jul-180.98未发现恶性肿瘤人群证据。待处理
21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial.J Natl Compr Canc NetwPMID 39019060无 PMCID2024-Jul-170.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.Br J DermatolPMID 38629497无 PMCID2024-Jul-160.98未发现恶性肿瘤人群证据。待处理
An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases.Int J Radiat Oncol Biol PhysPMID 38218455无 PMCID2024-Jul-150.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.Ann Rheum DisPMID 38569851PMC120565892024-Jul-150.98未发现恶性肿瘤人群证据。待处理
Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis.RMD OpenPMID 39004432PMC112537522024-Jul-140.98未发现恶性肿瘤人群证据。待处理
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.Pharmacogenomics JPMID 38992025PMC113741282024-Jul-120.80The report is from a Phase III RCT in cancer patients, but its primary and reported outcome is the risk of a specific adverse event (hypertension), not the survival, progression, recurrence, death, or other time-to-event efficacy outcomes required for inclusion in this cohort.待处理
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.J Clin OncolPMID 38552197PMC112273052024-Jul-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.J Clin OncolPMID 38710003PMC112273002024-Jul-101.00命中用户提供的消化道肿瘤阳性参考集。待处理
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.J Clin OncolPMID 38759121PMC113770962024-Jul-100.95The study is an eligible Phase III randomized trial with a time-to-event endpoint, but the intervention is radiotherapy alone, not a drug-containing intervention. It does not meet the inclusion criterion for a drug-containing intervention.待处理
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.Antimicrob Agents ChemotherPMID 38780262PMC112324002024-Jul-090.98未发现恶性肿瘤人群证据。待处理
Deployment of attractive targeted sugar baits in western Zambia: installation, monitoring, removal, and disposal procedures during a Phase III cluster randomized controlled trial.Malar JPMID 38982496PMC112346562024-Jul-090.98未发现恶性肿瘤人群证据。待处理
Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI).Mod RheumatolPMID 37606691无 PMCID2024-Jul-060.98未发现恶性肿瘤人群证据。待处理
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.LancetPMID 38876133无 PMCID2024-Jul-061.00命中用户提供的消化道肿瘤阳性参考集。待处理
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.OncologistPMID 38394384PMC112249902024-Jul-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.BloodPMID 38643510PMC112514042024-Jul-040.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Donidalorsen for Hereditary Angioedema.N Engl J MedPMID 38819395无 PMCID2024-Jul-040.98未发现恶性肿瘤人群证据。待处理